Metabolic changes in normal appearing white matter in multiple sclerosis patients using multivoxel magnetic resonance spectroscopy imaging

Sun, Jie; Song, H.; Yang, Yong; Zhang, Kun; Gao, Xiuju; Li, Xiaopan; Li, Ni; Lin, Pan; Niu, Chen

doi:10.1097/md.0000000000006534

Cited by 21 publications

(19 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Almost half of the surveyed papers employed magnetic resonance spectroscopic imaging (MRSI) instead of single-voxel acquisition schemes, including echo-planar spectroscopic imaging (EPSI) (85, 89, 124, 144, 145, 221–223), and other CSI or spectroscopic imaging sequences encoded in two (25, 28, 30, 34, 36, 41, 43, 45, 50, 52, 54, 57, 60–62, 64–66, 68, 72, 73, 80, 81, 83, 87, 93, 94, 115, 119, 130, 131, 133, 135, 141, 159, 162–165, 167, 168, 174, 188, 191, 194, 204, 224–231) or three (102, 121, 122, 137, 202, 232, 233) spatial dimensions. MRSI offers the obvious advantage of enabling metabolic profiling over a large area of multiple tissue types, thereby enabling averaging over gray matter, white matter, and lesions within the same individual, enabling more robust estimates for the metabolic patterns of hypothetically pure tissue (102, 104, 163, 164).…”

Section: Spectral Acquisition and Processingmentioning

confidence: 99%

Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker

et al. 2019

View full text Add to dashboard Cite

Proton magnetic resonance spectroscopy (1H-MRS) offers a growing variety of methods for querying potential diagnostic biomarkers of multiple sclerosis in living central nervous system tissue. For the past three decades, 1H-MRS has enabled the acquisition of a rich dataset suggestive of numerous metabolic alterations in lesions, normal-appearing white matter, gray matter, and spinal cord of individuals with multiple sclerosis, but this body of information is not free of seeming internal contradiction. The use of 1H-MRS signals as diagnostic biomarkers depends on reproducible and generalizable sensitivity and specificity to disease state that can be confounded by a multitude of influences, including experiment group classification and demographics; acquisition sequence; spectral quality and quantifiability; the contribution of macromolecules and lipids to the spectroscopic baseline; spectral quantification pipeline; voxel tissue and lesion composition; T1 and T2 relaxation; B1 field characteristics; and other features of study design, spectral acquisition and processing, and metabolite quantification about which the experimenter may possess imperfect or incomplete information. The direct comparison of 1H-MRS data from individuals with and without multiple sclerosis poses a special challenge in this regard, as several lines of evidence suggest that experimental cohorts may differ significantly in some of these parameters. We review the existing findings of in vivo 1H-MRS on central nervous system metabolic abnormalities in multiple sclerosis and its subtypes within the context of study design, spectral acquisition and processing, and metabolite quantification and offer an outlook on technical considerations, including the growing use of machine learning, by future investigations into diagnostic biomarkers of multiple sclerosis measurable by 1H-MRS.

show abstract

Section: Spectral Acquisition and Processingmentioning

confidence: 99%

Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Marked damage to the frontal regions was also noticed in the study on patients with MS [44]. A different pattern of damage to NAWM was observed in a study of Asian patients with MS, which revealed that the largest decrease in NAA was in parietal NAWM [45].…”

Section: Discussionmentioning

confidence: 72%

Neurochemical Changes in the Brain and Neuropsychiatric Symptoms in Clinically Isolated Syndrome

Guenter

Bieliński

Bonek³

et al. 2020

JCM

View full text Add to dashboard Cite

To assess cognitive impairment and affective symptoms and their association with damage to normal-appearing white matter (NAWM) in patients with clinically isolated syndrome (CIS), we compared neuropsychological test scores between patients with CIS and healthy controls and examined correlations between these and proton magnetic resonance spectroscopy (1H-MRS) outcomes in patients with CIS. Forty patients with CIS and 40 healthy participants were tested with a set of neuropsychological tests, which included the Beck Depression Inventory (BDI) and the Hospital Anxiety and Depression Scale (HADS). Single-voxel 1H-MRS was performed on frontal and parietal NAWM of patients with CIS to assess ratios of N-acetyl-aspartate (NAA) to creatine (Cr), myo-inositol (mI), and choline (Cho), as well as mI/Cr and Cho/Cr ratios. Patients with CIS had lower cognitive performance and higher scores for the BDI and anxiety subscale of HADS than healthy controls. There were significant correlations between the following neuropsychological tests and metabolic ratios in the frontal NAWM: Stroop Color-Word Test and Cho/Cr, Symbol Digit Modalities Test and mI/Cr, as well as NAA/mI, Go/no-go reaction time, and NAA/Cho, as well as NAA/mI, Californian Verbal Learning Test, and NAA/Cr. BDI scores were related to frontal NAA/mI and parietal NAA/Cr and Cho/Cr ratios, whereas HADS-depression scores were associated with frontal NAA/Cr and NAA/mI and parietal NAA/Cr and Cho/Cr ratios. HADS-anxiety correlated with parietal NAA/Cr ratio. This study suggests that neurochemical changes in the NAWM assessed with single-voxel 1H-MRS are associated with cognitive performance and affective symptoms in patients with CIS.

show abstract

“…For example, brain metabolism plays a major role in pathogenesis of some neurological disorders such as Alzheimer’s disease 17 - 19 by hypometabolismpromoted Aβ deposition. 20 Furthermore, the findings based on proton magnetic resonance spectroscopy have shown the alteration of metabolite concentration in various areas of the brain in different neurometabolic disorders such as multiple sclerosis, 21 brain tumors, 22 , 23 epilepsy, 24 , 25 Alzheimer disease, 26 - 28 and dementia 29 is significantly correlated with cognitive decline. Based on the abovementioned studies, metabolic diseases of the brain can lead to changes in the structure and function of brain areas associated with cognition; most metabolic diseases of the brain cause changes in neuronal structure and cognitive decline.…”

Section: Cognitive Changes In Metabolic Syndromementioning

confidence: 99%

Cognitive Impairments and Associated Structural Brain Changes in Metabolic Syndrome and Implications of Neurocognitive Intervention

Kordestani-Moghadam

Assari

Nouriyengejeh

et al. 2020

Journal of Obesity & Metabolic Syndrome

View full text Add to dashboard Cite

Currently, metabolic syndrome has become a global health problem. Alterations in neurocognitive functions among patients with metabolic syndrome are important issues in this disorder. In this paper, studies on metabolic syndrome were reviewed and their importance emphasized for the benefit of experts and policy makers. Metabolic syndrome activates inflammatory mediators that disrupt brain metabolism. These mediators can be activated by metabolic inflammation and microvascular disorders and may further cause damage to the white matter and impair cognitive function. These alterations can result in serious changes in cognitive abilities. The association between cognitive changes and metabolic syndrome has been independently evaluated in several studies. In addition, some areas of research in the field of metabolic syndrome include the effectiveness of neurocognitive interventions to enhance normal behaviors or reduce risky behaviors in patients. Structural brain correlates of health-related behaviors provide a basis for designing more effective behavioral interventions by identifying the corresponding brain regions and using behavioral interventions.

show abstract

Metabolic changes in normal appearing white matter in multiple sclerosis patients using multivoxel magnetic resonance spectroscopy imaging

Abstract: Supplemental Digital Content is available in the text

Cited by 21 publications

References 42 publications

Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker

Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker

Neurochemical Changes in the Brain and Neuropsychiatric Symptoms in Clinically Isolated Syndrome

Cognitive Impairments and Associated Structural Brain Changes in Metabolic Syndrome and Implications of Neurocognitive Intervention

Contact Info

Product

Resources

About